summary
Introduced
01/22/2019
01/22/2019
In Committee
01/22/2019
01/22/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
191st General Court
Bill Summary
Relative to opioid drug manufacturer assessments. Mental Health, Substance Use and Recovery.
AI Summary
This bill establishes a new assessment on opioid drug manufacturers in Massachusetts. The assessment would be based on the ratio of each manufacturer's annual distribution and dispensing of opioid drugs in the state compared to the total statewide distribution and dispensing. The total annual assessment would not exceed $15 million, and the funds would go to the Opioid Treatment and Addiction Prevention Fund to support prevention, treatment, management, and research related to opioid addiction and alternative pain management. The Department of Public Health is required to promulgate regulations to implement the assessment within 180 days, and the assessment will take effect on June 30, 2020.
Committee Categories
Health and Social Services
Sponsors (22)
Michael Brady (D),
Gerry Cassidy (D),
Claire Cronin (D),
Josh Cutler (D),
Shawn Dooley (R),
Carolyn Dykema (D),
Lori Ehrlich (D),
Tricia Farley-Bouvier (D),
Carole Fiola (D),
Bill Galvin (D),
Randy Hunt (R),
Louis Kafka (D),
Hannah Kane (R),
Rady Mom (D),
Brian Murray (D),
Jim O'Day (D),
Sarah Peake (D),
Smitty Pignatelli (D),
Dave Rogers (D),
Jeff Roy (D),
Aaron Vega (D),
Bud Williams (D),
Last Action
Accompanied a new draft, see H4532 (on 03/09/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Document Type | Source Location |
---|---|
State Bill Page | https://malegislature.gov/Bills/191/H1703 |
Bill | https://malegislature.gov/Bills/191/H1703.pdf |
Loading...